Aim: Up to 25% of colorectal cancer patients will present PC during follow up. Numerous recent studies in selected group of patients with colorectal PC, treated with CRS + HIPEC and postoperative chemotherapy, report a 5-year survivals of 30-52%. The aggressiveness and surgical risk related to this treatment modality should outweigh the benefits achieved by other therapies. We present our survival results, as well as relevant prognostic indicators in overall survival. 
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